Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $276

Benzinga Newsdesk www.benzinga.com Positive 87.7%

Neg 0% Neu 0% Pos 87.7%

Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $270 to $276.